Brilinta granted FDA Priority Review for the reduction of subsequent stroke in patients who had an acute ischemic stroke or transient ischemic attack
9 July 2020 07:00 BST Brilinta granted FDA Priority Review for the reduction of subsequent strokein patients who had an acute ischemic stroke or transient ischemic attack Brilinta in combination with aspirin could be the first FDA-approved dualantiplatelet therapy to reduce the rate of stroke in these high-risk patients AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute